Key facts
- This page summarizes Dietrich John Pauls's Form 4 filing for DiaMedica Therapeutics Inc. (DMAC).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Jun 2024, 16:41.
Dietrich John Pauls - 01 Jun 2024 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- DMAC
- Reported as of
- 01 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2024, 16:41:13 UTC
- Prior SEC filing
- 26 Jun 2023
- Next SEC filing
- 03 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Amy E. Culbert, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Dietrich John Pauls filed Form 4 for DiaMedica Therapeutics Inc. (DMAC) on 03 Jun 2024.
Change
- Previous filing in this sequence was filed on 26 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DMAC
holding
Voting Common Shares, no par value per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 68,591
- Date
- 01 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DMAC
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +300,000
- Change %
- Price
- $0.000000
- Shares after
- 300,000
- Date
- 01 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 300,000
- Exercise price
- $2.90
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.
Footnote F2
Vests with respect to 25% of the underlying common shares on June 1, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2025.